Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)

Romero-Laorden, N; Lozano, R; Jayaram, A; López-Campos, F; Saez, MI; Montesa, A; Gutierrez-Pecharoman, A; ... Olmos, D; + view all Romero-Laorden, N; Lozano, R; Jayaram, A; López-Campos, F; Saez, MI; Montesa, A; Gutierrez-Pecharoman, A; Villatoro, R; Herrera, B; Correa, R; Rosero, A; Pacheco, MI; Garcés, T; Cendón, Y; Nombela, MP; Van de Poll, F; Grau, G; Rivera, L; López, PP; Cruz, J-J; Lorente, D; Attard, G; Castro, E; Olmos, D; - view fewer (2018) Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). British Journal of Cancer , 119 (9) pp. 1052-1059. 10.1038/s41416-018-0123-9 .

http://bit.ly/2slGiDB